Scientists from the Scripps Research Institute (TSRI) has made a major breakthrough in identifying an enzyme causing the production of a class of inflammatory lipid molecules in the brain. High levels of these molecules are responsible for the causing a rare inherited neurodegenerative disorder. This can potentially spell the way for a treatment by using a suitable drug to inhibit the particular enzyme.
The benefits of this enzyme may extend to other disorders involving brain inflammation such as multiple sclerosis, Alzheimer's, Parkinson's, ALS and secondary damage after stroke and head injuries. There is currently no effective pharmacological treatment for such inflammation.
"This finding is a good example of what can be gained from studying enzymes linked to rare human genetic disorders," said Benjamin F. Cravatt, chair of TSRI's Department of Chemical Physiology and member of TSRI's Skaggs Institute for Chemical Biology.
Read more at: http://www.medicalnewstoday.com/releases/287923.php
No comments:
Post a Comment